Opus Genetics raises $3.5M in private placement led by board chair for gene therapy manufacturing

Opus Genetics, Inc.

Issued 3,138,338 shares at ~$1.11/sh in private placement; gross proceeds $3.5M.
Led by board chair Cam Gallagher ($1M) and lead independent director Sean Ainsworth.
Proceeds to expedite manufacturing process development for gene therapy candidates OPGx-LCA5 and OPGx-BEST1.
Private placement closed August 25, 2025; exempt under Section 4(a)(2) and Regulation D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.